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Background: Niacin, a compound primarily used for its lipid altering properties, has
been shown to improve endothelial function with short term administration, via the
release of prostaglandins. We hypothesized that via these effects, niacin could lead to
reductions in pulmonary artery pressures.
Methods: Pilot study involving 32 subjects with known tricuspid regurgitation (TR)
and a Doppler jet velocity of 2.7 m/s or greater. Subjects were randomized in a 1:2:2
ratio to receive a single dose of either placebo, niacin 100mg or niacin 500mg
respectively in a double blinded, acute provocation study. Following baseline assess-
ment of TR jet velocity, blinded study drug was administered. At peak absorption of
niacin and maximal ﬂushing triggered by prostaglandin release (1 hour post-
administration), TR jet velocity was re-assessed. The study was powered to detect a
difference of 0.2  0.2 m/s in TR jet velocity between groups.
Results: Baseline TR jet velocity was 2.89  0.30 m/s. The mean change in Doppler
jet velocity was -0.024 0.15 m/s in the placebo group, compared to -0.041 0.27 m/s
with niacin 100 mg, and -0.065  0.17 m/s with niacin 500 mg. This trend was not
statistically signiﬁcant (ANOVA). The overall reduction in TR jet velocity observed
with niacin, (2.93  0.32 m/s to 2.87  0.42 m/s) was small and not statistically sig-
niﬁcant (P¼ 0.26). There was no observed effect among subgroups with above or below
median baseline TR Doppler jet velocities.
Conclusion: Single dose administration of immediate-release niacin 100 mg or 500
mg has no signiﬁcant effect on PA pressures at 1 hour post administration.
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Background: Hyperuricemia is a well-known risk factor for diabetes mellitus (DM)
and other cardiovascular diseases, but the relationship between hyperuricemia and
the development of new-onset DM is not clear. We evaluated the impact of hyper-
uricemia on the development of new-onset DM based on 5-year cumulative clinical
outcomes in Asian patients.
Methods: A total of 3,274 patients who did not have DM were enrolled. New-onset
DM was deﬁned as having a fasting blood glucose 126mg/dL or HbA1c 6.5%.
Hyperuricemia was deﬁned as uric acid 7.0 mg/dL. Baseline characteristics between
the hyperuricemia and control groups were matched with propensity score matching
(PSM, C-statistics¼0.731). 5-year cumulative incidence of new-onset DM was
compared between the two groups.
Results: At baseline, patients in the hyperuricemia group showed a higher prevalence
of male gender, hypertension and dyslipidemia. The hyperuricemia group had higher
levels of basal insulin, HOMA-IR, triglyceride and lower levels of HDL-C. Develop-
ment of new-onset DM was higher in the hyperuricemia group (13.5% vs. 7.9%,
p<0.001). After PSM, baseline characteristics were well balanced (C-statics¼0.731).
After adjustment with cox-regression analysis, hyperuricemia remained to be an inde-
pendent predictor of new-onset DM (OR 1.72, 95% CI 1.01 - 2.94, p¼0.045, ﬁgure).
Conclusions:Hyperuricemia was shown to be an independent predictor of new-onset
DM. Therefore it may be suggested that uric acid levels should be included in the
prediction of DM and patients with hyperuricemia may beneﬁt from measures to
reduce the uric acid.Thrombosis
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Background: The concept of biodegradable polymer-based scaffolds has emerged as
an alternative to the permanent metallic device implants to treat a transient vascular
healing problem. The development of a suitable polymer has been challenging because
it must exhibit vascular biocompatibility while allowing time- and dose-controlled
antiproliferative drug release such that complete healing is achieved. The aims of this
study were to characterize intimal biocompatibility of biodegradable polymers and
drugs using screening assays of apoptosis, oxidative stress, proinﬂammatory mediators,
adhesion molecules, prothrombotic and antithrombotic mediators in endothelial cells.
Methods: Endothelial cell line EAHy926 were cultured in chamber slides coated with
poly-DL-lactide (PDLA) and paciltaxel for seven days. Flow cytometric analysis was
used to measure cytotoxicity, apoptosis (annexin V and 7-amino-actinomycin D
staining, 7-AAD), nitrotyrosine expression, thrombomodulin, tissue factor, cell
adhesion molecules (PECAM-1, P-selectin and PSGL-1), activated protein C re-
ceptor and co-stimulation modulators (CD40L, TNF receptor).
Results: Treatment of endothelial cells with PDLA and paclitaxel induced increase in
annexin V expression (4.4%) compared to control (0.3%), but not 7-AAD stained
dead cells, indicating enhanced apoptosis. Paciltaxel alone and in combination with
PDLA showed upregulation of tissue factor (38.8% vs control 7.3%) and down-
regulation of thrombomodulin (86.8% vs control 98.5%). Endothelial cells incubated
in PDLA and paciltaxel showed a marked increase in nitrotyrosine expression and
exhibited an apparent cell death compared to the negative control. Paciltaxel alone or
in combination with PDLA showed upregulation of microtubule-associated protein
1A/1B-light chain 3 (31.3% vs. control 5.0%) and p62 protein (56.4% vs. control
7.2%) indicating stimulation of autophagy. PDLA and paciltaxel had minimal effect
on the expression of cell adhesion molecules, activated protein C receptor, or co-
stimulation modulators.
Conclusion: The results indicate that PDLA and paciltaxel induce nitrative oxidative
stress, stimulate autophagy, promote prothrombotic mediators, and cytotoxicity in
endothelial cells. The study emphasizes endothelial biocompatibility screening of newly
evolving biodegradable polymers as drug carriers and bioresorbable vascular scaffolds.
